Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Inclusion Criteria: * Male or female patients aged 50 years or greater diagnosed with GA inside and/or outside of the fovea who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment. * Patient must provide new written informed consent for this OLE trial prior to participation. * Patient must have the ability to return for all trial visits for the duration of the 18-month trial. Exclusion Criteria: * Patient did not complete Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham), * Patient who had the study drug permanently withdrawn for an AE during ISEE2008 are not eligible. * Patient did not enroll into this OLE trial within the 90 day enrollment period. * Patient who is pregnant or nursing